Smith & Nephew SNATS (SNN) Stock Price, News & Analysis

Company Overview

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair. Its sports medicine and ear, nose & throat (ENT) division develops arthroscopic visualization systems, shavers and biologic adjuncts to support minimally invasive procedures in joints and soft tissues. The company’s trauma and extremities segment offers a range of plates, nails and fixation devices for fracture management, while its advanced wound management arm markets negative pressure wound therapy systems, collagen dressings and antimicrobial solutions for chronic and acute wounds.

Headquartered in London and listed on both the London Stock Exchange and the New York Stock Exchange (NYSE: SNN), Smith & Nephew serves healthcare providers in more than 100 countries across Europe, North America, Latin America, Asia Pacific and the Middle East. Its global manufacturing footprint encompasses production sites in the United Kingdom, United States, Germany, Switzerland, Costa Rica and China, supported by research and development centers in key markets to drive product innovation and regulatory compliance.

Under the leadership of Chief Executive Officer Roland Diggelmann, Smith & Nephew continues to focus on expanding its digital surgery offerings, strengthening its biologics pipeline and pursuing targeted acquisitions to complement its core businesses. The company emphasizes long-term partnerships with hospitals and clinicians, investing in training programs, data-driven solutions and value-based healthcare initiatives to improve patient outcomes and optimize the total cost of care.

Key Stats

• Today's Range: $37.19 to $37.49
• 50-Day Range: $29.17 to $37.53
• 52-Week Range: $23.69 to $37.65
• Volume: 484,378 shs
• Average Volume: 941,554 shs
• Market Capitalization: $16.41 billion
• P/E Ratio: 17.35
• Dividend Yield: 2.38%
• Price Target: $36.00
• Consensus Rating: Hold

Smith & Nephew SNATS Stock Analysis - MarketRank™

Smith & Nephew SNATS scored higher than 58% of companies evaluated by MarketBeat, and ranked 457th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Smith & Nephew SNATS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Smith & Nephew SNATS has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 18.34%

Earnings Growth

Earnings for Smith & Nephew SNATS are expected to grow by 18.34% in the coming year, from $1.69 to $2.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Smith & Nephew SNATS is 17.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.85.

Price to Earnings Ratio vs. Sector

The P/E ratio of Smith & Nephew SNATS is 17.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.27.

Price to Earnings Growth Ratio

Smith & Nephew SNATS has a PEG Ratio of 1.03. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

Smith & Nephew SNATS has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.60% of the float of Smith & Nephew SNATS has been sold short.

Short Interest Ratio / Days to Cover

Smith & Nephew SNATS has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Smith & Nephew SNATS has recently decreased by 2.94%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Smith & Nephew SNATS pays a meaningful dividend of 2.39%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Smith & Nephew SNATS does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Smith & Nephew SNATS is 41.20%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 44.50% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.60% of the float of Smith & Nephew SNATS has been sold short.

Short Interest Ratio / Days to Cover

Smith & Nephew SNATS has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Smith & Nephew SNATS has recently decreased by 2.94%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.87

News Sentiment

Smith & Nephew SNATS has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Smith & Nephew SNATS this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Smith & Nephew SNATS to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Smith & Nephew SNATS is held by insiders.

Percentage Held by Institutions

Only 25.64% of the stock of Smith & Nephew SNATS is held by institutions.

SNN Stock Analysis - Frequently Asked Questions

How have SNN shares performed this year?

Smith & Nephew SNATS's stock was trading at $24.58 on January 1st, 2025. Since then, SNN stock has increased by 52.4% and is now trading at $37.4720.

How were Smith & Nephew SNATS's earnings last quarter?

Smith & Nephew SNATS, Inc. (NYSE:SNN) posted its earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.59.

Who are Smith & Nephew SNATS's major shareholders?

Smith & Nephew SNATS's top institutional investors include Bank of Montreal Can (0.78%), River Road Asset Management LLC (0.73%), Scharf Investments LLC (0.48%) and Brandes Investment Partners LP (0.37%).

How do I buy shares of Smith & Nephew SNATS?

Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Smith & Nephew SNATS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew SNATS investors own include JPMorgan Chase & Co. (JPM), Johnson & Johnson (JNJ), PepsiCo (PEP), Taiwan Semiconductor Manufacturing (TSM), McDonald's (MCD), Sanofi (SNY) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/17/2014
• Today: 8/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:SNN
• CIK: 845982
• Web: www.smith-nephew.com
• Phone: 441923477100
• Fax: 44-20-7930-3353
• Employees: 17,349
• Year Founded: 1856

Price Target and Rating

• Average Price Target for Smith & Nephew SNATS: $36.00
• High Price Target: $36.00
• Low Price Target: $36.00
• Potential Upside/Downside: -3.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 17.35
• Forward P/E Ratio: 22.17
• P/E Growth: 1.03
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 3.00
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $5.81 billion
• Price / Sales: 2.82
• Cash Flow: $3.16 per share
• Price / Cash Flow: 11.86
• Book Value: $12.64 per share
• Price / Book: 2.96

Miscellaneous

• Outstanding Shares: 437,980,000
• Free Float: 433,601,000
• Market Cap: $16.41 billion
• Optionable: Optionable
• Beta: 0.68